Amersham’s Metastron (Strontium-89)
Injectable cancer pain drug is being launched June 28 at a list price of $1,850 for a 4 mCi single-dose vial. One dose, delivered in an outpatient procedure, "usually is effective for an average of six months." Metastron, approved by FDA on June 18, ("The Pink Sheet" June 21, T&G-1) will be promoted to urology and medical oncology specialists by Zeneca and to nuclear medicine, radiopharmacy, and radiation oncology experts by Amersham, under a worldwide co-promotion agreement.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth